KLA-Tencor Corp. (KLAC) Falls 3.44% for January 15

Equities Staff |

One of the S&P 500’s big losers for Friday January 15 was KLA-Tencor Corp. (KLAC). The company’s stock fell 3.44% to $64.37 on volume of 1.26 million shares.

The stock opened the day at 64.11 and traded between a low of $63.64 and a high of $65.18. The stock finished the day down $2.29 per share. KLA-Tencor Corp. has an average daily volume of 2.18 million and a total float of 155.95 million shares. The 50-day SMA for KLA-Tencor Corp. is $67.30 and its 200-day SMA is $57.65. The high for the stock over the last 52 weeks is $71.13 and the low is $44.95.

KLA-Tencor Corp is a supplier of process control and yield management solutions for the semiconductor and related nanoelectronics industries.

KLA-Tencor Corp. is centered in Milpitas, CA, and has 5,880 employees. Today’s trading day leaves the company with a market cap of $10.04 billion. The company has a P/S ratio of n/a, P/B ratio of 34.06, and a 22.4.

For a complete fundamental analysis analysis of KLA-Tencor Corp., check out Equities.com’s Stock Valuation Analysis report for KLAC. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…